Key Financials

Consolidated Key Figures

(thousands of €, if not stated otherwise)	Nine months ended September 30, 2025	Nine months ended September 30, 2024	Year ended December 31, 2024
Income statement
Supply revenues	29,332	19,124	34,863
Collaboration revenues	182,094	181,030	240,786
Total net revenues	211,426	200,154	275,649
Cost of sales	-29,281	-19,124	-34,863
R&D expenses	-351,909	-238,270	-335,459
S&M, G&A expenses	-109,017	-93,190	-134,438
Impairment of the cell therapy business	-204,753	–	–
Other operating result	21,374	24,813	40,773
Operating loss	-462,160	-125,617	-188,338
Net financial results	-20,124	103,501	185,253
Taxes	19,287	1,710	1,803
Net loss from continuing operations	-462,997	-20,406	-1,282
Net profit from discontinued operations, net of tax	1,735	69,181	75,364
Net profit/loss (-)	-461,262	48,775	74,082
Income statement from discontinued operations
Product net sales	–	11,395	11,475
Collaboration revenues	–	26,041	26,041
Total net revenues	–	37,436	37,516
Cost of sales	–	-2,182	-1,693
R&D expenses	-10,369	-13,600	-8,152
S&M, G&A expenses	-766	-10,797	-12,607
Other operating result	11,406	55,167	56,180
Operating profit	271	66,024	71,244
Net financial results	1,996	3,255	4,218
Taxes	-532	-98	-98
Net profit from discontinued operations, net of tax	1,735	69,181	75,364
Balance sheet
Cash and cash equivalents	64,458	55,523	64,239
Financial investments	2,985,656	3,283,256	3,253,516
R&D incentives receivables	149,339	175,202	172,611
Assets	3,511,914	4,172,202	4,135,719
Shareholders’ equity	2,446,963	2,862,570	2,896,939
Deferred income	896,431	1,127,932	1,071,352
Other liabilities	168,520	181,700	167,428
CASH FLOW
Operational cash burn (*)	-145,129	-321,278	-373,961
Cash flow used in operating activities	-209,995	-260,657	-320,026
Cash flow generated from investing activities	216,191	152,237	220,597
Cash flow used in financing activities	-2,868	-3,320	-4,924
Increase/decrease (-) in cash and cash equivalents	3,328	-111,740	-104,353
Effect of currency exchange rate fluctuation on cash and cash equivalents	-3,109	453	1,782
Cash and cash equivalents at the end of the period	64,458	55,523	64,239
Financial investments at the end of the period	2,985,656	3,283,256	3,253,516
Total financial investments and cash and cash equivalents at the end of the period	3,050,114	3,338,779	3,317,755
FINANCIAL RATIOS
Number of shares issued at the end of the period	65,897,071	65,897,071	65,897,071
Basic and diluted earnings/loss (-) per share	-7	0,74	1,12
Share price at the end of the period (in €)	29.16	25.88	26.52
Total group employees at the end of the period (number)	471	683	704

(*)The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

• the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (-) financing activities
• the net proceeds or cash used, if any, related to the acquisition or disposal of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities
• the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.